MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: Perceptive Avisors
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)*
Organization & Developments: Protagonist
Parents
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)*
Children
2018: Protagonist Therapeutics: Any Hope After Monday's Debacle?_seekingalpha.com
2020: Biotech Analysis Central Preview Series: Protagonist Therapeutics
2020: Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
2021: Highly Rated Protagonist Stock Takes A Hit After Study Mice Develop Tumors
2021: Protagonist Therapeutics: A Well-Hedged Biotech With A Potential Blockbuster In Rusfertide
2023: Protagonist Therapeutics: Evaluating Rusfertide's Potential For PV
2024: Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
2024: Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
2024: Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
2024: Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
2024: The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
2025: Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
2025: Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck_ seekingalpha.com
2026: Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
Jumps
*Key People: Protagonist
Finance & Acquisitions: Protagonist